Ionis Pharmaceuticals (NASDAQ:IONS) Rating Reiterated by Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $60.00 price target on the stock. A number of other research firms have also recently commented on IONS. Citigroup raised shares of Ionis […]

Related Keywords

Nevada ,United States ,China ,C Frank Bennett ,Hedge Funds Weigh In On Ionis Pharmaceuticals ,Almanack Investment Partners ,Ionis Pharmaceuticals Trading Down ,Nevada Inc ,Ionis Pharmaceuticals Inc ,Whittier Trust Co ,Citigroup ,Ionis Pharmaceuticals ,Ionis Pharmaceuticals Company Profile ,Analyst Recommendations For Ionis Pharmaceuticals ,China Universal Asset Management Co ,Needham Company ,News Ratings For Ionis Pharmaceuticals Daily ,Securities Exchange Commission ,Free Report ,Moderate Buy ,Pharmaceuticals Trading Down ,Get Free Report ,Frank Bennett ,Exchange Commission ,Investment Partners ,Financial Advisors ,China Universal Asset Management ,Universal Asset Management ,Ionis Pharmaceuticals Daily ,Nasdaq Ions ,Lions ,Medical ,46433010 ,Reiterated Rating ,Needham Company Llc ,